INTRODUCTION
============

For decades, it has been recognized that men have a higher age-adjusted risk of ischemic cardiovascular (CVD) events compared to women \[[@R1]-[@R4]\], thus generating hypotheses that sex steroids contribute to CVD risk. However, it is still unknown if and how sex steroids contribute to ischemic CVD risk for several reasons. First, the results from endogenous sex steroid studies, i.e. where participants are not using exogenous sex steroids, have conflicted with results from randomized trials of sex steroid therapy. Recent reports of endogenous sex steroids suggest that low endogenous testosterone (T) is associated with increased risk of CVD events in men \[[@R5]-[@R7]\], while randomized trials of T therapy suggest that higher T levels may increase CVD risk \[[@R8], [@R9]\]. Similarly, among women, low endogenous estradiol (E2) associated with the postmenopause has been thought to contribute to increased CVD risk in women \[[@R10]\], but estrogen supplementation trials suggest that higher E2 may be harmful \[[@R11]\]. Thus, exogenous sex steroid trials may not reflect naturally occurring physiology.

Second, few prospective endogenous sex steroid studies have reported upon both ischemic stroke events and ischemic coronary heart disease (CHD) events. Data from studies examining subclinical atherosclerosis \[[@R12]-[@R15]\] as well as events \[[@R16], [@R17]\] suggest that the relationships between endogenous sex steroids and CVD differ by vascular bed. Therefore, evaluation of risk factors would ideally examine CHD and ischemic stroke separately. As ischemic strokes may consist of strokes from thrombotic as well as atherogenic risk factors, hemostatic risk factors as well as classic CVD risk factors would be examined; however, such examinations are few.

In this report, we summarize the results from prospective studies of endogenous sex steroids and incident ischemic CVD events in men and women. Particular focus is placed upon how patterns differed between ischemic stroke and CHD events and how patterns differed between men and women. We discuss these findings in the context of purported mechanisms, randomized trial results, and sex steroid measurement issues. We conclude with a summary of major gaps in the existing literature and directions for future research.

PROSPECTIVE ENDOGENOUS SEX STEROID REPORTS
==========================================

In May 2014, we performed a PubMed review using the following key words, limited to the English language: sex steroid AND (longitudinal OR prospective) AND (cardiovascular OR stroke OR coronary disease), which yielded 916 articles. In order to capture nested case-control studies, we performed another search substituting "case-control OR case-cohort" for "longitudinal OR prospective" which yielded 311 citations but only one additional citation not identified in the original search \[[@R18]\]. The publications retained for inclusion assessed endogenous serum levels of estrogens and/or androgens in relation to events attributed to ischemic CVD, ischemic stroke, or ischemic CHD. We focused upon prospective relationships between sex steroids and events. Reports that focused on only risk factors, subclinical atherosclerosis, or mortality were not included. Reports examining only effects of exogenous steroid therapy were not included.

Seventeen studies that met inclusion criteria examined men, and eight studies that met inclusion criteria examined women (Table **[1](#T1){ref-type="table"}**). Studies in men spanned middle-age to older age. Most of the studies in women focused on mid-life and older women who were postmenopausal; the two studies that included premenopausal women only reported upon androgens, \[[@R18], [@R19]\] which have less variation with the menstrual cycle than estrogens \[[@R20]\]. Most studies examined the relationships between sex steroid levels and incident events before and after adjustment for conventional CVD risk factors. In general, as indicated in Table **[1](#T1){ref-type="table"}**, studies that reported significant associations before adjustment also reported significant associations after adjustment, and studies that reported absence of significant associations before adjustment also reported lack of associations after adjustment. There were several exceptions \[[@R21]-[@R24]\] which are discussed in more detail below.

SUMMARY OF PROSPECTIVE STUDIES IN MEN
=====================================

Among men, six studies reported upon the prospective relationship between T or DHT (dihydrotestosterone) and incident ischemic CVD events. Three studies reported a linear relationship, \[[@R16], [@R25],[@R26]\], one study reported a J-shaped relationship \[[@R21]\], and one study reported a U-shaped relationship \[[@R6]\] between T or DHT \[[@R6]\] and incident events, i.e. extremes of T or DHT were associated with a higher risk of CVD events. Two studies reported no significant relationship \[[@R27],[@R28]\]. The single report examining DHT did not find an association between T and incident events \[[@R6]\].

Five studies reported upon the relationship between T or DHT and incident ischemic stroke, with one report noting a linear relationship \[[@R29]\] and another report noting a U-shaped relationship with DHT but not with T \[[@R5]\]. Three studies reported no significant relationship between total T level and incident stroke events \[[@R16], [@R21],[@R30]\], although the bioavailable fraction of T (the "active" portion not bound to sex hormone binding globulin or SHBG) was associated after but not before adjustment for CVD risk factors in one of these reports \[[@R21]\], and the association between T and incident stroke was of borderline significance in the other two reports \[[@R16], [@R30]\].

Nine studies reported upon the relationship between T and incident CHD events, with only two reports noting any relationship between T and incident CHD events \[[@R16], [@R21]\]. Of note, the majority of studies examining CHD in men were conducted prior to 2004 \[[@R31]-[@R36]\], in contrast to studies examining ischemic stroke or a composite of CVD events.

Among men, six studies reported upon the prospective relationship between estrone (E1) or E2 and incident ischemic CVD events. One study reported that a higher level of E2 was associated with incident events, \[[@R27]\] while the other studies reported no relationship \[[@R16], [@R21], [@R25], [@R28],[@R37]\]. Three studies reported upon the relationship between E2 and incident ischemic stroke, with one study noting a higher level of E2 was associated with incident ischemic stroke \[[@R30]\], and two other studies noting no relationship \[[@R16], [@R21]\]. Eight studies reported upon the relationship between E1 or E2 and incident CHD events; \[[@R16],[@R21], [@R31]-[@R34], [@R36], [@R38]\] no relationship was reported.

Among men, no prospective studies noted associations between other endogenous sex steroids and incident CVD events, with the exception of one study that reported a higher level of dehydroepiandrosterone (DHEAS) was associated with a higher risk of ischemic CHD \[[@R35]\].

One review attempted to pool risk estimates of T and incident CVD events \[[@R26]\]. Significant between-study heterogeneity was noted by year of publication, in that studies published after January 2007 noted stronger relationships. The relationship between low T and incident events was stronger in older men (hazard ratio 0.84, 95% CI 0.76, 0.92) than in younger men (HR 1.01, 95% CI 0.95, 1.08). Another report attempted to pool risk estimates of E2 and incident CVD events and noted that the quality of the E2 assay, presumably based upon coefficients of variation and detection limits, was a significant source of heterogeneity. E2 was not noted to have any association with CVD risk \[[@R39]\].

SUMMARY OF PROSPECTIVE STUDIES IN WOMEN
=======================================

There were relatively few prospective studies of endogenous sex steroids and ischemic CVD events in women compared to men. As noted earlier, all of the studies focused exclusively upon postmenopausal women except for two reports \[[@R18],[@R19]\]. Only three prospective studies examined the relationship between endogenous T and ischemic CVD risk in women; one study reported that a lower level of T was associated with a higher risk of ischemic CVD, \[[@R19]\] and two other studies reported no association \[[@R17],[@R22]\]. One of these studies noted that lower free androgen index, representing the proportion of T not bound to SHBG, was associated with higher risk of CVD events before but not after adjustment for CVD risk factors \[[@R22]\]. The one study which examined the association between T and ischemic stroke in women reported no association \[[@R17]\]. Of the two studies that examined the relationship between T and ischemic CHD events, one report noted that a U-shaped relationship, i.e. lower and higher levels of T were associated with increased risk of incident events, \[[@R7]\] while the other reported no association \[[@R17]\].

Among women, one report noted that higher levels of DHEAS were associated with greater risk of ischemic stroke \[[@R18]\]. While SHBG is not a sex steroid but may influence active T and E2 levels through binding, one report examined SHBG levels but found no association with CVD risk \[[@R22]\].

POTENTIAL MECHANISMS
====================

In this review, the sex steroids most frequently examined in relation to CVD included the androgen T and the estrogen E2. T and E2 are directly produced primarily by gonadal organs (Fig. **[1](#F1){ref-type="fig"}**). In both men and women, T is aromatized to E2, particularly in adipose tissue. T may also undergo 5 alpha-reduction in the gonads, the prostate gland in men, and hair follicles to form the more potent DHT compound; DHT cannot be converted to E2. Both albumin and SHBG bind to T and E2, but binding with albumin is relatively weak while binding to SHBG renders T and E2 inactive. DHEAS is secreted primarily by the adrenal gland and is the most abundant steroid in postmenopausal women. DHEAS is a precursor of both androgens and estrogens; \[[@R40]\] metabolites of DHEAS include androstenedione (A), which subsequently may be metabolized to T or estrone (E1), which is an E2 precursor. E1 and E2 are produced by the gonads and may also be produced when T is aromatized in adipose tissue. DHEAS is also the source of additional steroid hormone metabolites that may have different local effects \[[@R40]\] or have both androgenic and estrogenic activity \[[@R41]\].

Sex steroid receptors are present throughout the cardiovasculature, immunoregulatory cells, and platelets. Sex steroids have genomic and non-genomic effects, \[[@R42]-[@R44]\] i.e. sex steroids affect gene transcription but also can have effects that are mediated through pathways other than protein or RNA synthesis (Fig. **[1](#F1){ref-type="fig"}**) \[[@R45]\]. Generally, animal and in-vitro studies suggest that androgens might be pro-inflammatory, thrombotic, and atherogenic while estrogens attenuate inflammation \[[@R46]\]. Potential mechanisms have been summarized in several recent reviews \[[@R42]-[@R45]\]. Briefly, in vascular endothelial cells, estrogens increase synthesis of nitric oxide synthase (NOS) and also increase NOS activity through phosphorylation, thus enabling NO-induced vasodilation. Estrogens enhance production of prostacyclin, another vasodilator, while androgens favor vasoconstriction through thromboxane. In addition, both androgens and estrogens have been identified as inflammatory regulators through the presence of sex steroid receptors on neutrophils, monocytes, macrophages, and platelets. Acute E2 infusion reduces secretion of interleukin-6 and fibrinogen and can reduce adenosine-diphosphate (ADP) induced platelet aggregation, while androgens may increase platelet sensitivity to ADP and cyclooxygenase. Finally, higher levels of E2 are associated with lower levels of plasminogen activator inhibitor-1 and tissue plasminogen activator levels, markers of fibrinolysis \[[@R47]\]. Androgen and estrogen receptors are also present in adipocytes with a greater proportion of androgen receptors in visceral fat, suggesting sex steroid effects could be further mediated by adipokines such as C-reactive protein, adiponectin, and leptinb \[[@R48]-[@R50]\]. The summary effect of these changes may increase the risk of thrombosis particularly in the cerebrovasculature, with or without underlying atherogenesis.

Both endogenous estrogen and androgen levels are associated with CVD risk factors in prospective studies. Thus, it is possible that sex steroid effects upon CVD risk may be mediated through classic CVD risk factors, in addition to or instead of the mechanisms noted above. Androgens have been noted to predict future levels of CVD risk factors; in general, higher androgen levels in men have been associated with more favorable CVD risk factor profiles in men, but less favorable profiles in women \[[@R51]\]. Specifically, lower levels of T in men are associated with diabetes and elevations in glucose, \[[@R51]\] blood pressure, \[[@R52]\] and lipids \[[@R53]\]. In contrast, higher levels of T in women are associated with diabetes, \[[@R51]\] elevations in blood pressure, \[[@R54], [@R55]\] and adverse lipid levels \[[@R56]\]. Although young women have higher E2 levels and more favorable CVD risk factor profiles than older women, higher endogenous E2 levels are associated with poorer classical CVD risk factors in postmenopausal women \[[@R51], [@R54]\]. These associations may explain why higher E2 levels are associated with greater CVD risk in women, even as higher E2 levels are thought to enable vasodilation, decreased platelet aggregation, and more favorable hemostatic profiles. Obesity likely has bidirectional relationships with sex steroids \[[@R51]\] and may influence both risk factor profiles as well as vascular reactivity and coagulation \[[@R57]\].

RANDOMIZED TRIALS
=================

Randomized trials of T supplementation have not supported the hypothesis that supplementing with T can decrease CVD risk. A 2011 meta-analysis noted that androgen-deprivation therapy for prostate cancer was not associated with significant increases in CVD death \[[@R58]\]. Supplementation may actually increase risk of CVD events. Among men, a meta-analysis of T therapy conducted in 2013 including 27 trials noted that T therapy increased the risk of any CVD events (odds ratio \[OR\] 1.54, 95% confidence interval \[CI\] 1.09, 2.18), and the magnitude of effect did not vary by baseline T level, suggesting that T therapy was harmful regardless of whether men had low T \[[@R9]\].

Similarly, randomized trials of E2 supplementation among women with low levels of endogenous E2 (i.e. postmenopausal women) have not supported the hypothesis that supplementing with estrogen can decrease CVD risk. As in men, supplementation with exogenous sex steroids in women may actually increase risk of CVD outcomes. The Women's Health Initiative (WHI) randomized postmenopausal women without known CVD to oral conjugated equine estrogen and medroxyprogesterone acetate vs. placebo and noted a significant increase in the risk of CHD events \[[@R59]\] and ischemic stroke \[[@R60]\]. Among participants in the WHI estrogen-alone trial, the risk of CHD events was similar in therapy vs. placebo groups \[[@R61]\] and the risk of ischemic stroke was higher among women randomized to estrogen \[[@R62]\]. A similar lack of benefit has been observed for estrogen supplementation in secondary prevention studies. In the Women's Estrogen for Stroke Trial, \[[@R63]\] which randomized women with a recent mild stroke or transient ischemic attack to estrogen therapy vs. placebo, estrogen therapy did not reduce stroke risk. In the Heart Estrogen-Progestin Replacement Study, which randomized women with known CHD to estrogen/progestin vs. placebo, women randomized to estrogen had an increased risk of another CHD event, although a significant increased risk in stroke was not observed \[[@R64]\]. Younger postmenopausal women do not appear to benefit from estrogen therapy any more than older postmenopausal women: long-term follow-up in the WHI studies did not find that estrogen therapy was associated with benefit in younger as opposed to older women, although the magnitude of risk was smaller in younger women, probably due to their lower risk for CVD generally \[[@R59]\]. In randomized trials of younger women, preliminary presentations have noted that estrogen therapy is not associated with a significantly lower burden of coronary artery calcification \[[@R65]\].

Theoretically, exogenous sex steroid supplementation delivered transdermally rather than orally may more closely approximate a healthy hormonal milieu. Oral estrogen therapy leads to elevations in SHBG level and subsequently decreases bioavailable fractions of sex steroids, and these "first-pass" effects through the liver could influence CVD risk \[[@R66]\]. Oral, but not transdermal estrogen therapy, is associated with enhanced platelet reactivity \[[@R67]\]. Although analyses of the WHI Observational Study noted that transdermal E2 was not associated with lower risk of CHD compared with oral conjugated equine estrogen for CHD events or stroke, \[[@R68]\] women were not randomized to therapy route and thus an association may have been confounded by healthier women using transdermal rather than oral therapy. Different oral estrogen types may be lead to different risk, despite the fact that oral estrogen formulations are all metabolized by the liver. Although the mechanism is not understood, one case-control study noted that women using oral conjugated estrogen therapy had higher thrombin potential-based normalized activated protein C sensitivity ratio, indicating a stronger clotting propensity, than women using oral E2, and the former also had an increased risk of CVD events \[[@R69]\]. No trials or prospective studies assess the differential effects of estrogen formulation upon outcomes such as incident CVD. Among men, T therapy in randomized trials that have reported CVD outcomes have typically delivered T transdermally via gels or patches or intramuscularly, thus avoiding first-pass liver effects and the question of whether such effects might be contributing to increased risk \[[@R70]\].

These results from randomized studies are consistent with the observation that exogenous therapy, presumably resulting in an increased serum level of a sex steroid, does not benefit CVD risk. This may be due to adverse effects of the therapy unrelated to serum sex steroid levels, supraphysiologic sex steroid levels that do not mimic endogenous levels, or absence of an association between sex steroids and CVD risk per se with confounding by other factors such as obesity or classic CVD risk factor levels. Rexrode et al noted that the relationship between sex steroid levels and incident CVD events among estrogen users and non-users differed, in that there were associations between bioavailable T and incident CVD among non-users but not among estrogen users before adjustment for CVD risk factors \[[@R22]\]. The majority of estrogen therapy trials have not measured sex steroid levels. However, comparisons of sex steroid levels in the Study of Women's Health Across the Nation, a prospective observational study which measured endogenous sex steroid levels, noted that premenopausal women had E2 levels of 40.8 pg/ml (SD 4.3 pg/ml) vs. 41.5 pg/ml (SD 2.5 pg/ml) among women using estrogen and progestin therapy vs. 14.8 pg/ml (SD 0.7 pg/ml) among postmenopausal women not using any E2 therapy \[[@R71]\]. This result suggests that conventional oral conjugated estrogen therapy yielded similar serum E2 levels to those observed in premenopausal women, and therefore supraphysiologic sex steroid levels with supplementation are probably not the reason for the lack of agreement between trials and observational studies.

Of note, estrogen therapy randomized trials in women have targeted a particular serum E2 value, although oral and transdermal therapy approximately double total E2 concentrations.\[[@R66]\] Similarly, trials of T therapy have not noted that the risks of benefit of T therapy vary by baseline level of T, even as T levels after replacement are often not recorded continuously \[[@R9]\]. While the cutpoint for hypogonadism varied, approximately 10.4-16.4 nmol/l or 300 ng/dl to 475 ng/dl is a common range for hypogonadism in clinical trials \[[@R9], [@R72]-[@R75]\]. If doses exceeded about 1000 ng/dl or 34.7 nmol/l or were below about 250 ng/dl or 8.7 nmol/l, dose adjustments occurred in several \[[@R72], [@R73], [@R76]\] but not other studies \[[@R74], [@R75], [@R77]\]. Thus, there is not a consensus on what constitutes supraphysiologic sex steroid levels among older men and women.

ISSUES OF MEASUREMENT
=====================

There has been ongoing debate on how to best assess endogenous sex steroid levels, particularly in the older populations at greatest risk for ischemic CVD events but also with difficult to detect sex steroid levels. Newer assays may afford more sensitive detection levels \[[@R78], [@R79]\]. It is therefore possible that more recent studies may have greater power to detect an association between sex steroid levels and ischemic CVD risk. In support of this possibility, more recent prospective cohort studies \[[@R5], [@R6],[@R17], [@R19], [@R21],[@R24], [@R28]\] have tended to report the presence of significant relationships between endogenous sex steroids and ischemic CVD risk.

Currently, there is no single measurement standard for sex steroids, although there is a consensus that harmonization is needed \[[@R80], [@R81]\]. Older adults have low levels of sex steroids but are at highest risk of CVD events. The detection limit of the particular sex steroid assay used may also be a crucial factor, e.g. T levels in older women are very low. Direct assays, that is, assays performed without an extraction step, are considered unreliable, and thus measurement is generally done after extraction and chromatography \[[@R80],[@R81]\]. Direct measurement of unbound or free T and E2 can be done using dialysis or ultrafiltration. These methods require relatively large sample volume and are expensive. Therefore, equations that estimate free or bioavailable T and E2 are often substituted for direct measurement \[[@R82], [@R83]\]. These equations incorporate total T and E2 measurements using mass spectrometry or radioimmunoassay, SHBG measurements, and albumin measurements or estimations. In this review, the majority of the studies examining relationships between sex steroids and CVD used indirect radioimmunoassay with the exception of 2 cohorts of elderly men, \[[@R5], [@R6], [@R16]\] and it remains to be seen whether the use of mass spectrometric techniques currently endorsed by medical societies leads to a different pattern of results \[[@R78], [@R79]\].

Mass spectrometry relies on an extraction step, typically using serial liquid-liquid extraction with isolation of lipid fractions, reconstitution of the organic phase, followed by removal of phospholipids and other components \[[@R84]\]. Liquid chromatography-isotopic dilution mass spectrometry is then used to quantify total sex steroid amounts. Sample preparation is usually automatically conducted using mass through-put, although occasionally done by hand \[[@R84]\]. The minimal cross-reactivity of these assays with other sex steroids may make such methods more accurate than indirect radioimmunoassays as well as offering lower detection limits. The Centers for Disease Control and Prevention (CDC) has led a hormone standardization program designed to harmonize the measurement of T levels, with an emphasis on mass spectrometry particularly in low-androgen populations. Briefly, participating laboratories would send aliquots which were then tested independently in a blinded fashion by the CDC; the majority of assays relied upon liquid chromatography tandem mass spectrometry. A range of 2.50 to 1,000 ng/dl was tested. In order to meet CDC standards, the means needed to be less than 6.4% \[[@R85]\].

GAPS IN THE LITERATURE
======================

Our report highlights the need for investigation in several areas. First, there is a paucity of prospective evaluations in women generally. Specific examinations of incident stroke vs. CHD events are needed for women; only a single European report examines the relationship between endogenous sex steroids for both ischemic stroke and CHD in women \[[@R17]\]. The two reports in men that examined both ischemic stroke and CHD noted statistically significant relationships between T and CHD, but not T and ischemic stroke \[[@R16], [@R21]\]. Examinations of both T and E2 are needed in women, rather than the traditional focus upon E2 levels only.

There is a lack of epidemiologic investigations regarding the differential mechanisms of endogenous sex steroids upon ischemic stroke vs. CHD, beyond classic CVD risk factors. Due in part to the lack of studies which directly compare relationships between sex steroids and stroke vs. CHD, it is unknown how particular factors might be influential for one vascular bed compared to another. Additional exploration of how sex steroids may interact with biomarkers, e.g. inflammatory measures or coagulation factors, to affect ischemic stroke risk vs. CHD risk are also needed. Such risk factors also include adiposity: examinations of the relationship between obesity and androgen levels need to include precise measures of the mass of fat depots in order to determine how changes in depot size affect sex steroid profiles and vice-versa.

Finally, there are no studies that report relationships of sex steroids among blacks and whites separately or non-Hispanics and Hispanics, which is particularly important given the higher risk of stroke among blacks and Hispanics \[[@R86]\]. Among men and women in the Atherosclerosis Risk in Communities cohort (ARIC), age-adjusted incidence of stroke was 2.4 in middle-aged white men and women, but 9.7 in black men and 7.2 in black women per 1000 person years \[[@R87]\]. Among Mexican-Americans, these risk ratios are roughly similar \[[@R88]\]. These disparities persisted in older age groups. Age-adjusted incidence of coronary events were 3.6 in white men and 2.1 in white women, but 5.6 in black men and 3.8 in black women per 1000 person-years \[[@R87]\]. Table **[1](#T1){ref-type="table"}** shows relationships between sex steroids and CVD events in whites, and Asians, and mixed populations in which the number of CVD events was too small to perform race or ethnicity-specific analyses. However, it is well-recognized that the risk for incident CHD events in black women exceeds that in white women and (to a lesser extent) in black men compared to white men, \[[@R89]\] and that the risk for incident ischemic stroke in black women exceeds than in white women and in black men compared to white men at younger ages, before survival biases comparisons \[[@R3]\]. Moreover, a 2014 meta-analysis reported that black men have slightly but significantly higher endogenous free T (the active portion not bound to sex hormone binding globulin or SHBG) levels than white men \[[@R90]\]. E2 is also higher in black men than white men, even after adjustment for adiposity \[[@R91], [@R92]\]. Some, \[[@R93]\] although not all, \[[@R94]\] studies suggest that postmenopausal black women have higher endogenous E2 levels than white women even after consideration of adiposity.

Whether or not these differences contribute to racial-ethnic differences in CVD events is not known. Genomewide Association Studies (GWAS) have identified hundreds of loci associated with atherosclerosis and cardiovascular disease, but each of these loci account for a small part of the variance of disease and are present to different extents across populations \[[@R95]\]. In addition, the implicated variants are linked to disease, but not thought to be truly causal in most instances \[[@R95]\]. Targeted and genomewide sequencing can identify rare genetic variants, although these are unlikely to explain atherosclerosis on a population-wide basis. To date, these genes have focused upon classic cardiovascular and inflammatory risk factors, but have not examined shared loci with sex steroids.

CONCLUSIONS
===========

Although sex comparisons and comparisons of pre- and postmenopausal women have suggested a role for sex steroids in the pathophysiology of incident CVD events, it is unclear if and how sex steroids affect CVD risk. Prospective studies of endogenous sex steroid levels suggest that simplistic models of elevated androgens explaining greater CVD risk in men and decreased estrogens explaining decreased CVD risk in women are incorrect. These studies also suggest that randomized trials of sex steroid therapy may not extend naturally occurring pathophysiology, as the pattern of endogenous associations is opposite to the risks observed in randomized trials. To determine the contribution of sex steroids to CVD risk, studies are needed that examine men with measurement tools sensitive enough to detect lower androgen levels in older populations with separate assessment of stroke and CHD outcomes. Studies in women are few, and further investigations need to extend beyond investigation of estrogen levels only. Due to significant risk differences in ischemic CVD events by race/ethnicity, reports are needed that examine relationships separately for blacks and whites. Exploration of shared lock between sex steroids and cardiovascular events across populations might also be explored.
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Relationships between sex steroids and ischemic cardiovascular disease (CVD), stroke, and coronary heart disease (CHD) events in prospective studies. (+) indicate that higher levels of sex steroid are associated with higher risk and (-) indicate that lower levels of sex steroid associated with higher risk in a linear manner. T=testosterone, DHT=dihydrotestosterone, E1=estrone, E2=estradiol, SHBG=sex hormone binding globulin, DHEAS = dehydroepiandrosterone, A=androstenedione

  Men                              Ischemic CVD (Stroke or CHD)       Ischemic Stroke       Ischemic CHD                                                                                      
  -------------------------------- ---------------------------------- --------------------- ------------------ ----------------------- ------------ ------------ ------------- -------------- -------------
  Cauley 1987 \[[@R31]\]                                                                                                                                         T: none       E1, E2: none   A: none
  Barrett-Connor 1988 \[[@R32]\]                                                                                                                                 T: none       E1, E2: none   A: none
  Phillips 1988 \[[@R33]\]                                                                                                                                       T: none       E2: none        
  Yarnell 1993 \[[@R34]\]                                                                                                                                        T: none       E2: none        
  Hautanen 1994 \[[@R35]\]                                                                                                                                       T: none                      DHEAS: (-)‡
  Mikulec 2004 \[[@R36]\]                                                                                                                                        T: none       E1, E2: none   
  Arnlov 2006 \[[@R27]\]           T: none                            E2: (-)               DHEAS: none                                                                                        
  Abbott 2007 \[[@R30]\]                                                                                       none\*                  E2: (+)¶                                                
  Akishita 2009 \[[@R25]\]         T: (-)                             E2: none              DHEAS: none                                                                                        
  Nilsson 2009 \[[@R37]\]                                             E2: none                                                                                                                 
  Vikan 2009 \[[@R38]\]                                                                                                                                          T: none       E2: none       SHBG: none
  Yeap 2009 \[[@R29]\]                                                                                         T: (-)\*                                                                        
  Ohlsson 2011 \[[@R16]\]          T: (-)                             E2: none              SHBG: none         T: none\#               E2: none     SHBG: none   T: (-)        E2: none       SHBG: none
  Ruige 2011 \[[@R26]\]†‡          T: (-)                                                                                                                                      E2: none        
  Vandenplas 2012 \[[@R39]\]†                                         E2: none                                                                                                                 
  Haring 2013 \[[@R28]\]           T: none                            E2: none              DHEAS: none                                                                                        
  Soisson 2013 \[[@R21]\]          T: J-shaped                        E2: none              SHBG: none         T: J-shaped             E2: none     SHBG: none   T: J-shaped   E2: none       SHBG: none
  Shores 2014 \[[@R5]\]                                                                                        DHT: U-shaped, T none                                                          
  Shores 2014 \[[@R6]\]            DHT: U-shaped, T none                                                                                                                                      
  **Women**                        **Ischemic CVD (Stroke or CHD)**   **Ischemic Stroke**   **Ischemic CHD**                                                                                  
  **T/DHT**                        **E1/E2**                          **Other**             **T/DHT**          **E1/E2**               **Other**    **T/DHT**    **E1/E2**     **Other**      
  Rexrode 2003 \[[@R22]\]          T: none§                           E2: none              SHBG: none                                                                                         
  Nilsson 2009 \[[@R37]\]                                             E2: none                                                                                                                 
  Laughlin 2010 \[[@R7]\]                                                                                                                                        T: U-shaped                   
  Lee 2010 \[[@R23]\]                                                                                                                  E2: (+)¶     SHBG: none                                 
  Sievers 2010 \[[@R19]\]          T: (-)                                                                                                                                                      
  Chen 2011 \[[@R24]\]                                                                                                                                                         E2: noneщ       
  Scarabin 2012 \[[@R17]\]         T: none                            E2: (+)                                  T: none                 E2: none\#                T: none       E2: (+)         

^\*^Outcome = ischemic and hemorrhagic stroke, †Systematic review or meta-analysis; ‡Significant association in elderly but not middle-aged men; §Lower free androgen index associated with higher risk, but not after adjustment for CVD risk factors; \# Higher bioavailable estradiol associated with higher risk, but not after adjustment for CVD risk factors; \#Borderline, p\<0.10.
